Sub-cutaneous infliximab for perianal Crohn's disease: the BioLap-Rem multicentre study from the GETAID. Andre M, Kirchgesner J, Laharie D, Guillo L, et al. Am J Gastroenterol 2025 Aug 28. doi: 10.14309/ajg.0000000000003755.

Read + Share

Amedeo Smart

Independent Medical Education

Andre M, Kirchgesner J, Laharie D, Guillo L, et al. Sub-cutaneous infliximab for perianal Crohn's disease: the BioLap-Rem multicentre study from the GETAID. Am J Gastroenterol 2025 Aug 28. doi: 10.14309/ajg.0000000000003755.
PMID: 40874971